' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

OPPERMANN KATRIN - ehem. Angehörige/r dieser Universität

Publikationen

17 SCI-PubMed Publikationen

2019

Beiträge in Fachzeitschriften

Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study.
Auer, M; Hegen, H; Sellner, J; Oppermann, K; Bsteh, G; Di Pauli, F; Berger, T; Deisenhammer, F
BRAIN BEHAV. 2019; 9(7): e01332
Originalarbeiten (Zeitschrift)

2017

Beiträge in Fachzeitschriften

From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.
Harrer, A; Pilz, G; Oppermann, K; Sageder, M; Afazel, S; Haschke-Becher, E; Rispens, T; de Vries, A; McCoy, M; Stevanovic, V; Hitzl, W; Trinka, E; Kraus, J; Sellner, J; Wipfler, P;
Clin Immunol. 2017; 176: 87-93.
Originalarbeiten (Zeitschrift)

2015

Beiträge in Fachzeitschriften

High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.
Harrer, A; Pilz, G; Wipfler, P; Oppermann, K; Sellner, J; Hitzl, W; Haschke-Becher, E; Afazel, S; Rispens, T; van der Kleij, D; Trinka, E; Kraus, J;
Clin Exp Immunol. 2015; 180(3):383-392
Originalarbeiten (Zeitschrift)
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer, A; Wipfler, P; Pilz, G; Oppermann, K; Haschke-Becher, E; Afazel, S; Kraus, J; Trinka, E; Sellner, J;
Int J Mol Sci. 2015; 16(9): 21832-21845.
Originalarbeiten (Zeitschrift)

2014

Beiträge in Fachzeitschriften

A routine-qualified flow cytometric method for the identification of multiple sclerosis patients with reduced therapy efficiency under natalizumab
Oppermann, K; Harrer, A; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Sellner, J; Deisenhammer, F; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2014; 38(1): 17-23.
Originalarbeiten (Zeitschrift)
Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Afazel, S; Haschke-Becher, E; Sellner, J; Trinka, E; Kraus, J;
Acta Neurol Scand. 2014; 129(3):e12-e15
Originalarbeiten (Zeitschrift)

2013

Beiträge in Fachzeitschriften

Tumefactive MS lesions under fingolimod: a case report and literature review.
Pilz, G; Harrer, A; Wipfler, P; Oppermann, K; Sellner, J; Fazekas, F; Trinka, E; Kraus, J;
Neurology. 2013; 81(19): 1654-1658.
Originalarbeiten (Zeitschrift)
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Sellner, J; Koczi, W; Harrer, A; Oppermann, K; Obregon-Castrillo, E; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Clin Exp Immunol. 2013; 173(3):381-389
Originalarbeiten (Zeitschrift)

2012

Beiträge in Fachzeitschriften

Isolated leptomeningeal infiltration of a primary CNS B-cell lymphoma diagnosed by flow cytometry and confirmed by necropsy.
Broussalis, E; Hutterer, M; Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Haschke-Becher, E; Golaszewski, S; Schönauer, U; Weis, S; Killer-Oberpfalzer, M; Mc Coy, M; Trinka, E; Kraus, J;
Acta Neurol Scand. 2012; 126(3):e11-e16
Fallberichte
Flow cytometry and drug monitoring of natalizumab saturation of immune cells in multiple sclerosis
Harrer, A; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, L; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 377-382.
Originalarbeiten (Zeitschrift)
Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
Harrer, A; Pilz, G; Einhaeupl, M; Oppermann, K; Hitzl, W; Wipfler, P; Sellner, J; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
PLoS One. 2012; 7(2):e31784
Originalarbeiten (Zeitschrift)
Overview of laboratory methods to monitor innovative treatment regimens in multiple sclerosis
Kraus, J; Pilz, G; Wipfler, P; Holl, B; Oppermann, K; Golaszewski, SM; Harrer, A
LABORATORIUMSMEDIZIN. 2012; 36(6): 389-396.
Übersichtsarbeiten
Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.
Pilz, G; Harrer, A; Oppermann, K; Wipfler, P; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Mult Scler. 2012; 18(4):506-509
Originalarbeiten (Zeitschrift)
Future relevance of CSF biomarkers in modern MS treatment
Pilz, G; Wipfler, P; Harrer, A; Holl, B; Oppermann, K; Golaszewski, SM; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 383-388.
Originalarbeiten (Zeitschrift)

2011

Beiträge in Fachzeitschriften

Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
Harrer, A; Wipfler, P; Einhaeupl, M; Pilz, G; Oppermann, K; Hitzl, W; Afazel, S; Haschke-Becher, E; Strasser, P; Trinka, E; Kraus, J;
J Neuroimmunol. 2011; 234(1-2):148-154
Originalarbeiten (Zeitschrift)
Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options.
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Trinka, E; Kraus, J;
Drug Discov Today. 2011; 16(1-2):8-21
Übersichtsarbeiten
Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler, P; Oppermann, K; Pilz, G; Afazel, S; Haschke-Becher, E; Harrer, A; Huemer, M; Kunz, A; Golaszewski, S; Staffen, W; Ladurner, G; Kraus, J;
Mult Scler. 2011; 17(1):16-23
Originalarbeiten (Zeitschrift)